With each new drug discovery, Gilead seeks to improve the care of millions of patients living with life-threatening diseases around the world, including regions where access to medicine is limited or does not yet exist.

Gilead recognises that patients and communities often face challenges in accessing the best possible care, and we know that passion for scientific discovery alone — and that Gilead alone — cannot solve these challenges.

This is why, through our grant programmes in the UK and Ireland, Gilead supports patient advocacy organisations, healthcare professionals and nonprofit groups that work tirelessly in local communities to improve people’s lives day after day.

Gilead provides a range of funding opportunities for innovative and inspiring projects in the UK and Ireland, which improve health access, eliminate barriers to healthcare, advance education for healthcare professionals and support local communities.

Providing Access

Gilead believes medicines should be accessible to all people who need them, regardless of where they live or what resources they have. Political, social and geographical barriers often prevent people around the world from accessing the best possible care. We work with partners and grantees to help overcome those barriers.

Reducing Disparities

At Gilead, we fund projects that support underserved communities, which have systematically experienced greater social or economic obstacles to receiving healthcare.

Advancing Medical Education

Gilead recognises education is key to effective disease prevention and long-term disease management. We help community organisations by supporting disease awareness programs for patients and expanding knowledge and skills for healthcare professionals.

Supporting Local Communities

With more than 13,000 employees working in 35+ countries around the world, we understand how important it is for people of all backgrounds to live in vibrant local communities. Gilead funds initiatives that promote the wellbeing and improvement of the communities and cities in which our employees live and work.

UK-UNB-0259 July 2021